Fostering interactions among industry, investors, government, and academia

Pfizer Panel and Networking Event: Approaching R&D Collaboration from a “Developability” Mindset

Please note: this event is in the Pfizer building - 1 Portland Street.

Time: 4 PM - 7 PM
Location: Pfizer, 1 Portland Street, Cambridge, MA 02139
RSVP: Eventbrite

Join Pfizer on Thursday, September 26th for a panel discussion on approaching R&D collaboration from a “developability” mindset, followed a networking reception. They'll examine how to address developability challenges and discuss integrated molecular design strategies, exploring questions like:

  • What does a pharma quality data package look like?
  • Is developability embedded within your drug discovery plans?
  • Have you evaluated your candidates for pharmaceutical properties and ease of scale-up before locking down your final candidate/molecular design?

The panel will assemble current collaborators and key players in Pfizer’s due diligence process:

  • Nello Mainolfi, President and CSO, Kymera Therapeutics 
  • Weining Lu, MD, MS, FASN, Associate Professor of Medicine, Pathology & Laboratory Medicine, Nephrology Section, Department of Medicine, Boston University School of Medicine, Boston Medical Center  
  • Anthony Barry, Senior Director, Pfizer External Science and Innovation
  • Chris O’Donnell, Executive Director, Pfizer Ventures 
  • Janet Buhlmann, Senior Principal Scientist, Pfizer Centers for Technology and Innovation
  • Jennifer Liras, Vice President, Pfizer Medicine Design 
  • Laura Lin, Executive Director, Pfizer BioMolecule Design

The discussion will be followed by the announcement and introduction of this year’s winners of the Pfizer-sponsored LabCentral Golden Ticket(s) and a networking reception.

Registration begins at 4:00 pm; the program will begin at 4:30. Registration is required, so be sure to save your spot now!